NCT03729609View on ClinicalTrials.gov

"Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Untreated CD30-Positive Hodgkin's Lymphoma"

CompletedOBSERVATIONAL

Enrollment

113

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

September 27, 2023

Study Completion Date

September 27, 2023

Conditions

Untreated CD30-Positive Hodgkin's Lymphoma

Interventions

DRUG

Brentuximab vedotin (Genetical Recombination)

Brentuximab vedotin Intravenous Infusion

Trial Locations (1)

Unknown

Takeda Selected Site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY